CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice

Abstract

Cyclin‐dependent kinase (CDK) 4/6 inhibitors are integral treatment for advanced hormone receptor positive breast cancer; however, venous thromboembolic events (VTE) occurred in 1%‐5% of clinical trial patients. Thrombosis rates in the real‐world setting remain unclear. We aimed to define the rate of thromboembolic events, risk factors for thrombosis on CDK 4/6 inhibitors and evaluate the Khorana VTE risk score as a predictive tool for VTE in patients on CDK 4/6 therapy.